MedTrace Logo

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

NCT00451152 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.

Conditions

  • Open-angle Glaucoma

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.

OTHER

Anecortave Acetate Vehicle

Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry, Ph.D. · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00451152 on ClinicalTrials.gov